Tags

Type your tag names separated by a space and hit enter

Cannabidiol: pharmacology and therapeutic targets.
Psychopharmacology (Berl). 2021 Jan; 238(1):9-28.P

Abstract

RATIONALE

Cannabidiol (CBD) products lacking regulatory approval are being used to self-treat a myriad of conditions and for their unsubstantiated health benefits. The scientific evidence supporting these claims largely arises not from controlled clinical trials, but from the recognition that CBD has numerous biological targets. Yet, CBD is commonly consumed and often in over-the-counter products that are unapproved and of unknown composition. Epidiolex® is the only product that has undergone rigorous pharmacokinetic assessment and testing in clinical trials; it was approved as a non-scheduled drug by the U.S. Food and Drug Administration for the treatment of intractable childhood-onset seizures. However, studies investigating CBD for other medical conditions are limited in number and often lack the scientific rigor, controls, or sample sizes required to draw clinically meaningful conclusions. Although Epidiolex® is safe for human consumption, recent changes in regulation of commercially available CBD products have resulted in limited quality control and products marketed with unknown CBD bioavailability. Even scientifically rigorous studies have used different sources of CBD and different suspension vehicles for administration, making it difficult to compare results among studies and resolve mixed outcomes.

OBJECTIVES

This paper reviews the molecular targets, pharmacokinetics, and safety and abuse liability of CBD; additionally, the extant evidence on its potential therapeutic effects for neurological disorders, pain, inflammation, conditions related to immune function, psychiatric disorders, and substance use are described.

Authors+Show Affiliations

Center on Drug and Alcohol Research, University of Kentucky, 845 Angliana Ave, Lexington, KY, 40508, USA. Stevie.Britch@uky.edu. Department of Behavioral Science, University of Kentucky, Lexington, KY, 40508, USA. Stevie.Britch@uky.edu.Center on Drug and Alcohol Research, University of Kentucky, 845 Angliana Ave, Lexington, KY, 40508, USA. Department of Behavioral Science, University of Kentucky, Lexington, KY, 40508, USA.Center on Drug and Alcohol Research, University of Kentucky, 845 Angliana Ave, Lexington, KY, 40508, USA. Department of Behavioral Science, University of Kentucky, Lexington, KY, 40508, USA. Department of Pharmacology, University of Kentucky, Lexington, KY, 40508, USA. Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, 40508, USA. Department of Psychiatry, University of Kentucky, Lexington, KY, 40508, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33221931

Citation

Britch, Stevie C., et al. "Cannabidiol: Pharmacology and Therapeutic Targets." Psychopharmacology, vol. 238, no. 1, 2021, pp. 9-28.
Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). 2021;238(1):9-28.
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021). Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology, 238(1), 9-28. https://doi.org/10.1007/s00213-020-05712-8
Britch SC, Babalonis S, Walsh SL. Cannabidiol: Pharmacology and Therapeutic Targets. Psychopharmacology (Berl). 2021;238(1):9-28. PubMed PMID: 33221931.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol: pharmacology and therapeutic targets. AU - Britch,Stevie C, AU - Babalonis,Shanna, AU - Walsh,Sharon L, Y1 - 2020/11/21/ PY - 2020/07/24/received PY - 2020/11/10/accepted PY - 2022/01/01/pmc-release PY - 2020/11/23/pubmed PY - 2021/2/27/medline PY - 2020/11/22/entrez KW - Cannabidiol KW - Cannabis KW - Human KW - Marijuana KW - Medical cannabis KW - Pharmacokinetics SP - 9 EP - 28 JF - Psychopharmacology JO - Psychopharmacology (Berl) VL - 238 IS - 1 N2 - RATIONALE: Cannabidiol (CBD) products lacking regulatory approval are being used to self-treat a myriad of conditions and for their unsubstantiated health benefits. The scientific evidence supporting these claims largely arises not from controlled clinical trials, but from the recognition that CBD has numerous biological targets. Yet, CBD is commonly consumed and often in over-the-counter products that are unapproved and of unknown composition. Epidiolex® is the only product that has undergone rigorous pharmacokinetic assessment and testing in clinical trials; it was approved as a non-scheduled drug by the U.S. Food and Drug Administration for the treatment of intractable childhood-onset seizures. However, studies investigating CBD for other medical conditions are limited in number and often lack the scientific rigor, controls, or sample sizes required to draw clinically meaningful conclusions. Although Epidiolex® is safe for human consumption, recent changes in regulation of commercially available CBD products have resulted in limited quality control and products marketed with unknown CBD bioavailability. Even scientifically rigorous studies have used different sources of CBD and different suspension vehicles for administration, making it difficult to compare results among studies and resolve mixed outcomes. OBJECTIVES: This paper reviews the molecular targets, pharmacokinetics, and safety and abuse liability of CBD; additionally, the extant evidence on its potential therapeutic effects for neurological disorders, pain, inflammation, conditions related to immune function, psychiatric disorders, and substance use are described. SN - 1432-2072 UR - https://www.unboundmedicine.com/medline/citation/33221931/Cannabidiol:_pharmacology_and_therapeutic_targets_ L2 - https://dx.doi.org/10.1007/s00213-020-05712-8 DB - PRIME DP - Unbound Medicine ER -